GPRC5D-Targeted CAR T Cells for Myeloma

Overview of attention for article published in New England Journal of Medicine, September 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
Good Attention Score compared to outputs of the same age and source (67th percentile)

Mentioned by

news: 33 news outlets
blogs: 4 blogs
twitter: 133 X users
patent: 20 patents

facebook: 1 Facebook page
guideline: 2 clinical guideline sources
podcasts: 2 podcasts

Readers on

mendeley: 229 Mendeley

So far, Altmetric has seen 5 posts from 4 blogs.

New blood cancer therapy treats seven in 10 patients

Whats New, 10 Dec 2022

‘Revived’ for Blood Cancer Patients as Experimental Therapy Treats 73 PERCENT of Patients in Global Clinical…

Phage Therapy Saves Toddler's Life: Index #69

Codon Magazine, 03 Oct 2022

This year marks the 100-year anniversary of phage therapies. How fitting, then, that a paper out this week tells the story of a…

Phage Therapy Saves Toddler's Life: Index #69

Codon Magazine, 03 Oct 2022

This year marks the 100-year anniversary of phage therapies. How fitting, then, that a paper out this week tells the story of a…

CAR T-cell therapy produces impressive results in first clinical trial in patients with multiple myeloma

news-medical.net, 29 Sep 2022

A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein called GPRC5D antigen produced…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity, including 1 additional blog posts.